Biomedical subjects

C Hoegler

Publications and source records attributed to C Hoegler.

3 recordsLinked to original sources

PubMed1997

Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A.

BACKGROUND: Phosphodiesterase III (PDE3) inhibitors are inotropic agents used to treat congestive heart failure (CHF) and are less effective in patients with severe CHF. Little is known about relative changes in PDE3 activity or gene expression during the evolution of cardiomyopathy. METHODS AND RESULTS: In the present study, we evaluated temporal changes in PDE3A gene expression before and after pacing-induced CHF in nine mongrel dogs. Three weeks of left ventricular (LV) pacing produced LV end-diastolic pressures of 15+/-1.7 mm Hg, whereas overt CHF at 4 to 5 weeks was associated with LV end-diastolic pressures of 24+/-1.7 mm Hg; prepacing values were 6.6+/-0.6 mm Hg. Total RNA isolated from LV tissues was analyzed on Northern blots; 10 unpaced normal hearts served as tissue controls. Signals for PDE3A mRNAs (7, 8, and 10 kb) or PDE4D (7.6 kb) were normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or ribosomal 18S RNA. Before the onset of CHF, PDE3A/GAPDH ratios were not different between the control and 3-week paced groups. In contrast, all PDE3A/GAPDH ratios were selectively reduced by 52%, and PDE3A/18S was reduced by 70% (P<.05) in CHF; PDE4D/GAPDH (or 18S) was unchanged. LV tissues from four control and four CHF dogs were also processed to isolate cytosolic and microsomal membrane protein for cAMP PDE3 activity assays. CHF was associated with a significant 54% reduction (P<.05) in microsomal but not cytosolic PDE3 activity. CONCLUSIONS: Selective downregulation of PDE3A may account in part for the ineffectiveness of milrinone in the treatment of severe CHF.

3',5'-Cyclic-AMP Phosphodiesterases↗

PubMed1996

Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure.

Endothelium-dependent responses are depressed in coronary and peripheral blood vessels after the onset of pacing-induced heart failure in dogs and heart failure of various etiologies in humans. The present study was designed to examine whether these responses were due to decreases in the expression of endothelial cell NO synthase (ecNOS) and cyclooxygenase-1 (COX-1). After 1 month of left ventricular pacing, 8 mongrel dogs were monitored for heart failure as defined by clinical signs and left ventricular end diastolic pressures > 25 mm Hg. Total RNA and protein were isolated from endothelial cells scraped from the thoracic aorta and analyzed by Northern and Western blotting, respectively. Blots probed with 32P-labeled cDNAs for ecNOS and COX-1 were quantified densitometrically, and results were normalized against GAPDH or von Willebrand factor (vWF). In arbitrary units, the ratios of ecNOS to GAPDH were 2.66 +/- 0.77 (mean +/- SEM, n = 17) and 1.12 +/- 0.37 (n = 6 and the ratios of COX-1 to GAPDH were 1.52 +/- 0.52 and 0.56 +/- 0.15 before and after heart failure, respectively. These represent 56% to 64% (P < .05) reductions in ecNOS and COX-1 gene expression. There was no change in the ratios of either COX-1 or ecNOS to vWF. There was also a marked reduction in ecNOS protein after heart failure, estimated at 70%. A marked reduction in nitrite production, a measure of enzyme activity, from thoracic aortas in response to stimulation by either acetylcholine or bradykinin also occurred. To determine whether ecNOS and COX-1 could be independently regulated, an orally active NO-releasing agent, CAS 936, was given to 7 normal dogs for 7 days, and aortic ecNOS and COX-1 mRNAs were analyzed. The ratio of ecNOS to GAPDH was depressed by 52% (P < .05) in aortas from these dogs, whereas the ratio of COX-1 to GAPDH was unchanged. Similar results were found when data were normalized to vWF. These results suggest that at least two endothelial vasodilator gene products are reduced in heart failure, as opposed to a selective defect in NO synthase gene expression.

Animals↗

PubMed1989

Relationship between plasma atriopeptin concentration and function in the conscious primate.

The renal actions of atriopeptins (APs) 24, 21 and 28 were examined in the conscious primate, macaca fascicularis. AP-24 increased urine flow rate and sodium excretion 20- and 100-fold, respectively. The circulating form of the atriopeptins, AP-28, had similar, even slightly greater (25%) effects when compared to AP-24. AP-21 on the other hand had dramatically reduced effects, less than 20%, when compared to either AP-24 or AP-28. Infusion of AP-24 resulted in marked increases in plasma immunoreactive AP and in renal function. There were direct, significant linear relations between plasma levels and arterial pressure, heart rate, glomerular flow rate, urine flow rate, sodium and potassium excretion. However, the threshold for these effects was generally higher than expected, i.e., greater than 100 pg/ml. Interestingly, there was a 4-fold greater slope for sodium excretion when compared to other renal functions implying a distinctly different mechanism of action. Whereas, the plasma half-life of the peptide was 2 to 3 min, the biological half-life varied from 6 min for sodium excretion to 10 min for urine flow and potassium excretion. The increased slope for the relationship between sodium excretion and plasma AP concentration and the short half-life for sodium excretion indicate that the change in renal sodium handling is independent of urine flow rate and glomerular filtration rate. There is a direct and linear relationship between plasma peptides and renal function which may imply a cause and effect relationship. This extrapolation may, however, be valid only when plasma peptide levels are elevated markedly.

Animals↗